Molecular PET imaging in multicenter Alzheimer's therapeutic trials: current trends and implementation strategies.


Journal Article (Review)

Current therapeutic approaches for Alzheimer's disease (AD) have evolved to target specific molecular biological, metabolic and neuropathologic hallmarks of the disease. Since these approaches are hypothesized to be most effective at the earliest stages of the degenerative process, the ability to accurately detect and monitor progression of AD pathology and metabolic changes in vivo may accelerate the discovery and development of disease-modifying drugs. The use of molecular imaging biomarkers can not only enhance diagnostic accuracy and facilitate patient selection/stratification, but can also serve as key outcomes for clinical trials. In this review, we discuss emerging trends in the use of PET in AD drug development and provide a roadmap for harnessing its promise in multicenter clinical trials.

Full Text

Duke Authors

Cited Authors

  • Seibyl, J; Zubal, IG; Jennings, D; Marek, K; Doraiswamy, PM

Published Date

  • December 2011

Published In

Volume / Issue

  • 11 / 12

Start / End Page

  • 1783 - 1793

PubMed ID

  • 22091601

Pubmed Central ID

  • 22091601

Electronic International Standard Serial Number (EISSN)

  • 1744-8360

Digital Object Identifier (DOI)

  • 10.1586/ern.11.168


  • eng

Conference Location

  • England